Benno Nuding

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial

Ulrike Nitz, Oleg Gluz, Matthias Christgen et al. · Breast Cancer Research and Treatment · 2017 · 190 citations · Full text

Medicine, Oncology, Breast Oncology +16

West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer

Ulrike Nitz, Oleg Gluz, Michael Clemens et al. · Journal of Clinical Oncology · 2019 · 147 citations

Medicine, Oncology, Pharmacotherapy +16

Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer

Matthias Christgen, Oleg Gluz, Nadia Harbeck et al. · Cancer · 2020 · 57 citations · Full text

Medicine, Oncology, Surgery +15

The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer

Ulrike Nitz, Oleg Gluz, Hans Kreipe et al. · Therapeutic Advances in Medical Oncology · 2020 · 46 citations · Full text

Medicine, Endocrinology, Oncology +17

Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)—a translational analysis of the prospective WSG PlanB trial

Cornelia Kolberg-Liedtke, Oleg Gluz, Fred Heinisch et al. · Breast Cancer Research · 2020 · 39 citations · Full text

Medicine, Immunology, Oncology +17